Hypercoagulability, Parkinsonism, and Gaucher Disease

 

 Buy Article Permissions and Reprints

Abstract

Gaucher disease (GD) is a lysosomal disorder caused by inherited deficiency of glucocerebrosidase (GCase), resulting in the accumulation of glucocerebroside in macrophages, termed “Gaucher cells,” leading to multiorgan involvement, with hepatosplenomegaly, cytopenias, pulmonary hypertension, and skeletal complications. Various mutations, encoding the GCase gene, cause acute or chronic neuronopathic forms of the disease. The hallmark of GD is the macrophages infiltrating organs, bone marrow, and nervous system compromising their function by inflammation, infarcts, fibrosis, and neuronal damage. Coagulation abnormalities are frequent among GD patients due to reduced production and chronic consumption of coagulation factors. Splenic and bone infarcts often occur in GD patients, but hypercoagulability is not frequent. Detection of thrombophilic risk factors in GD patients may predict a more severe course of the disease. Clinical and genetic studies revealed an association between reduced GCase activity in carriers of GD mutations and GD patients and occurrence of Parkinson disease (PD) and showed that GCase gene mutations are risk factors for PD development. The mechanisms underlying the association of PD and GD are not yet elucidated and should be further explored, particularly the potential involvement of inflammation and coagulation in the neurovascular unit.

• References

• 1 Grabowski GA. Gaucher disease. Enzymology, genetics, and treatment. Adv Hum Genet 1993; 21: 377-441
  PubMedGoogle Scholar
• 2 Pennelli N, Scaravilli F, Zacchello F. The morphogenesis of Gaucher cells investigated by electron microscopy. Blood 1969; 34 (3) 331-347
  PubMedGoogle Scholar
• 3 Pastores GM. Gaucher's disease. Pathological features. Baillieres Clin Haematol 1997; 10 (4) 739-749
  CrossrefPubMedGoogle Scholar
• 4 Hughes DA, Pastores GM. Haematological manifestations and complications of Gaucher disease. Curr Opin Hematol 2013; 20 (1) 41-47
  CrossrefPubMedGoogle Scholar
• 5 Wong K, Sidransky E, Verma A , et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004; 82 (3) 192-207
  CrossrefPubMedGoogle Scholar
• 6 Leech RW, Shuman RM, Putnam WD, Rance F, Jewett TT. Gaucher's disease: a case history with extensive lipid storage in the brain. Am J Clin Pathol 1985; 83 (4) 516-519
  PubMedGoogle Scholar
• 7 Lin DS, Lin SP, Liang DC, Ho CS, Wu MC. Technetium-99m-HmPAO brain SPECT in infantile Gaucher's disease. Pediatr Neurol 1999; 20 (1) 66-69
  CrossrefPubMedGoogle Scholar
• 8 Orvisky E, Park JK, LaMarca ME , et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab 2002; 76 (4) 262-270
  CrossrefPubMedGoogle Scholar
• 9 Pratt PW, Kochwa S, Estren S. Immunoglobulin abnormalities in Gaucher's disease. Report of 16 cases. Blood 1968; 31 (5) 633-640
  PubMedGoogle Scholar
• 10 Shoenfeld Y, Gallant LA, Shaklai M, Livni E, Djaldetti M, Pinkhas J. Gaucher's disease: a disease with chronic stimulation of the immune system. Arch Pathol Lab Med 1982; 106 (8) 388-391
  PubMedGoogle Scholar
• 11 Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 2004; 32 (1) 214-217
  CrossrefPubMedGoogle Scholar
• 12 Wine E, Yaniv I, Cohen IJ. Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy. J Pediatr Hematol Oncol 2007; 29 (7) 451-457
  CrossrefPubMedGoogle Scholar
• 13 Rosenbaum H, Rowe JM. Immune and autoimmune phenomena in Type 1 Gaucher disease. In the 5th European Working Group on Gaucher Disease, Prague; 2002
  Google Scholar
• 14 Lester TJ, Grabowski GA, Goldblatt J, Leiderman IZ, Zaroulis CG. Immune thrombocytopenia and Gaucher's disease. Am J Med 1984; 77 (3) 569-571
  CrossrefPubMedGoogle Scholar
• 15 Rosenbaum H, Napso T, Bonstein L. Immune thrombocytopenia in type I Gaucher disease. Blood 2007; 110 (11) 3200a
  PubMedGoogle Scholar
• 16 Haratz D, Manny N, Raz I. Autoimmune hemolytic anemia in Gaucher's disease. Klin Wochenschr 1990; 68 (2) 94-95
  CrossrefPubMedGoogle Scholar
• 17 Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer 1993; 72 (1) 219-224
  CrossrefPubMedGoogle Scholar
• 18 Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105 (12) 4569-4572
  CrossrefPubMedGoogle Scholar
• 19 de Fost M, Vom Dahl S, Weverling GJ , et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006; 36 (1) 53-58
  CrossrefPubMedGoogle Scholar
• 20 Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 2005; 34 (3) 197-200
  CrossrefPubMedGoogle Scholar
• 21 Marsh RD, Killeen Jr RB, Agaliotis D. Gaucher's disease associated with chronic lymphocytic leukemia. South Med J 1993; 86 (4) 473-475
  CrossrefPubMedGoogle Scholar
• 22 Perales M, Cervantes F, Cobo F, Montserrat E. Non-Hodgkin's lymphoma associated with Gaucher's disease. Leuk Lymphoma 1998; 31 (5–6) 609-612
  PubMedGoogle Scholar
• 23 Manz M, Riessen R, Poll L , et al. High-grade lymphoma mimicking bone crisis in Gaucher's disease. Br J Haematol 2001; 113 (1) 191-193
  CrossrefPubMedGoogle Scholar
• 24 Horowitz M, Pasmanik-Chor M, Borochowitz Z , et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 1998; 12 (4) 240-244
  CrossrefPubMedGoogle Scholar
• 25 Grabowski GA, Horowitz M. Gaucher's disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol 1997; 10 (4) 635-656
  CrossrefPubMedGoogle Scholar
• 26 Lee RE. Pathology of Gaucher disease. In: Desnick RJ, Gatt S, Grabowski GA, , eds. Gaucher Disease: A Century of Delineation and Research (Progress in Clinical and Biological Research, Volume 95). New York: Alan R. Liss; 1981
  Google Scholar
• 27 Zimran A, Altarescu G, Rudensky B, Abrahamov A, Elstein D. Survey of hematological aspects of Gaucher disease. Hematology 2005; 10 (2) 151-156
  PubMedGoogle Scholar
• 28 Goker-Alpan O. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab 2011; 104 (4) 438-447
  CrossrefPubMedGoogle Scholar
• 29 Zimran A, Kay A, Gelbart T , et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992; 71 (6) 337-353
  CrossrefPubMedGoogle Scholar
• 30 Stone DL, Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. Adv Pediatr 1999; 46: 409-440
  PubMedGoogle Scholar
• 31 Mignot C, Gelot A, Bessières B , et al. Perinatal-lethal Gaucher disease. Am J Med Genet A 2003; 120A (3) 338-344
  CrossrefPubMedGoogle Scholar
• 32 Gupta N, Oppenheim IM, Kauvar EF, Tayebi N, Sidransky E. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis 2011; 46 (1) 75-84
  CrossrefPubMedGoogle Scholar
• 33 Forster J, Chambers JP, Peters SP, Lee RE, Glew RH. Acute neuropathic Gaucher disease in a black infant. J Pediatr 1978; 93 (5) 823-824
  PubMedGoogle Scholar
• 34 Jedidi H, Hamza B, Chadly A. [Gaucher's disease in infants with predominant neurological manifestations]. Tunis Med 1966; 44 (2) 85-95
  PubMedGoogle Scholar
• 35 Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr 2003; 143 (2) 273-276
  PubMedGoogle Scholar
• 36 Mignot C, Doummar D, Maire I, De Villemeur TB ; French Type 2 Gaucher Disease Study Group. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006; 28 (1) 39-48
  CrossrefPubMedGoogle Scholar
• 37 Adachi M, Wallace BJ, Schneck L, Volk BW. Fine structure of central nervous system in early infantile Gaucher's disease. Arch Pathol 1967; 83 (6) 513-526
  PubMedGoogle Scholar
• 38 Lloyd OC, Norman RM, Urich H. The neuropathology of infantile Gaucher's disease. J Pathol Bacteriol 1956; 72 (1) 121-131
  CrossrefPubMedGoogle Scholar
• 39 Sidransky E. New perspectives in type 2 Gaucher disease. Adv Pediatr 1997; 44: 73-107
  PubMedGoogle Scholar
• 40 Brady RO, Barranger JA. Glucosylceramide lipidosis: Gaucher's disease. In: Stanbury JB, Wijngaarden JB, Frederickson DS, Goldstein JL, Brown MS, , eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill; 1983: 842-856
  Google Scholar
• 41 Hannun YA, Bell RM. Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science 1987; 235 (4789) 670-674
  CrossrefPubMedGoogle Scholar
• 42 Suzuki K. Twenty five years of the “psychosine hypothesis”: a personal perspective of its history and present status. Neurochem Res 1998; 23 (3) 251-259
  CrossrefPubMedGoogle Scholar
• 43 Filocamo M, Mazzotti R, Stroppiano M, Grossi S, Dravet C, Guerrini R. Early visual seizures and progressive myoclonus epilepsy in neuronopathic Gaucher disease due to a rare compound heterozygosity (N188S/S107L). Epilepsia 2004; 45 (9) 1154-1157
  CrossrefPubMedGoogle Scholar
• 44 Benko W, Ries M, Wiggs EA, Brady RO, Schiffmann R, Fitzgibbon EJ. The saccadic and neurological deficits in type 3 Gaucher disease. PLoS ONE 2011; 6 (7) e22410
  CrossrefPubMedGoogle Scholar
• 45 Abrahamov A, Elstein D, Gross-Tsur V , et al. Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet 1995; 346 (8981) 1000-1003
  CrossrefPubMedGoogle Scholar
• 46 Barton NW, Brady RO, Dambrosia JM , et al. Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324 (21) 1464-1470
  CrossrefPubMedGoogle Scholar
• 47 Sidransky E. Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab 2004; 83 (1-2) 6-15
  CrossrefPubMedGoogle Scholar
• 48 Dahl N, Lagerström M, Erikson A, Pettersson U. Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am J Hum Genet 1990; 47 (2) 275-278
  PubMedGoogle Scholar
• 49 Kraoua I, Sedel F, Caillaud C , et al. A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients. Brain Dev 2011; 33 (2) 131-139
  CrossrefPubMedGoogle Scholar
• 50 Elstein D, Renbaum P, Levy-Lahad E, Zimran A. Incidence of thrombophilia in patients with Gaucher disease. Am J Med Genet 2000; 95 (5) 429-431
  CrossrefPubMedGoogle Scholar
• 51 Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 1997; 96 (3) 470-476
  CrossrefPubMedGoogle Scholar
• 52 Shitrit D, Rudensky B, Zimran A, Elstein D. D-dimer assay in Gaucher disease: correlation with severity of bone and lung involvement. Am J Hematol 2003; 73 (4) 236-239
  CrossrefPubMedGoogle Scholar
• 53 Granovsky-Grisaru S, Aboulafia Y, Diamant YZ, Horowitz M, Abrahamov A, Zimran A. Gynecologic and obstetric aspects of Gaucher's disease: a survey of 53 patients. Am J Obstet Gynecol 1995; 172 (4, Pt 1) 1284-1290
  CrossrefPubMedGoogle Scholar
• 54 Spectre G, Roth B, Ronen G , et al. Platelet adhesion defect in type I Gaucher disease is associated with a risk of mucosal bleeding. Br J Haematol 2011; 153 (3) 372-378
  CrossrefPubMedGoogle Scholar
• 55 Billett HH, Rizvi S, Sawitsky A. Coagulation abnormalities in patients with Gaucher's disease: effect of therapy. Am J Hematol 1996; 51 (3) 234-236
  CrossrefPubMedGoogle Scholar
• 56 Giona F, Palumbo G, Amendola A, Santoro C, Mazzuconi MG. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT). J Thromb Haemost 2006; 4 (8) 1831-1833
  CrossrefPubMedGoogle Scholar
• 57 Seligsohn U, Zitman D, Many A, Klibansky C. Coexistence of factor XI (plasma thromboplastin antecedent) deficiency and Gaucher's disease. Isr J Med Sci 1976; 12 (12) 1448-1452
  PubMedGoogle Scholar
• 58 Berrebi A, Malnick SD, Vorst EJ, Stein D. High incidence of factor XI deficiency in Gaucher's disease. Am J Hematol 1992; 40 (2) 153
  PubMedGoogle Scholar
• 59 Mitrovic M, Antic D, Elezovic I , et al. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher's disease. Platelets 2012; 23 (2) 143-149
  CrossrefPubMedGoogle Scholar
• 60 Deghady A, Marzouk I, El-Shayeb A, Wali Y. Coagulation abnormalities in type 1 Gaucher disease in children. Pediatr Hematol Oncol 2006; 23 (5) 411-417
  CrossrefPubMedGoogle Scholar
• 61 Tavil B, Balci YI, Karacan C, Sahin M, Kara A. Acquired von Willebrand disease in a Turkish boy with Gaucher disease. Pediatr Hematol Oncol 2007; 24 (4) 317-319
  CrossrefPubMedGoogle Scholar
• 62 Gerrits WB, van Aken WG, van der Meer J, Vreeken J. Splenomegaly associated with chronic consumption coagulopathy. Acta Med Scand 1974; 195 (5) 425-430
  PubMedGoogle Scholar
• 63 Kelsey H, Christopoulos C, Gray AA, Machin SJ. Acquired pseudo-pseudo Bernard-Soulier syndrome complicating Gaucher's disease. J Clin Pathol 1994; 47 (2) 162-165
  CrossrefPubMedGoogle Scholar
• 64 Gillis S, Hyam E, Abrahamov A, Elstein D, Zimran A. Platelet function abnormalities in Gaucher disease patients. Am J Hematol 1999; 61 (2) 103-106
  CrossrefPubMedGoogle Scholar
• 65 Givol N, Goldstein G, Peleg O , et al. Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease. Haemophilia 2012; 18 (1) 117-121
  CrossrefPubMedGoogle Scholar
• 66 Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Gaucher's disease. Lancet 2001; 358 (9278) 324-327
  CrossrefPubMedGoogle Scholar
• 67 Dickson DW, Fujishiro H, Orr C , et al. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 2009; 15 (Suppl. 03) S1-S5
  PubMedGoogle Scholar
• 68 Kövari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull 2009; 80 (4-5) 203-210
  CrossrefPubMedGoogle Scholar
• 69 Greffard S, Verny M, Bonnet AM , et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006; 63 (4) 584-588
  CrossrefPubMedGoogle Scholar
• 70 Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann Neurol 1997; 41 (1) 58-64
  CrossrefPubMedGoogle Scholar
• 71 Buchman AS, Shulman JM, Nag S , et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012; 71 (2) 258-266
  CrossrefPubMedGoogle Scholar
• 72 Dickson DW, Fujishiro H, DelleDonne A , et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008; 115 (4) 437-444
  CrossrefPubMedGoogle Scholar
• 73 Ross GW, Petrovitch H, Abbott RD , et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 2004; 56 (4) 532-539
  CrossrefPubMedGoogle Scholar
• 74 Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders?. Lancet Neurol 2010; 9 (11) 1128-1138
  CrossrefPubMedGoogle Scholar
• 75 Neumann J, Bras J, Deas E , et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132 (Pt 7) 1783-1794
  CrossrefPubMedGoogle Scholar
• 76 Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351 (19) 1972-1977
  CrossrefPubMedGoogle Scholar
• 77 Sidransky E, Nalls MA, Aasly JO , et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361 (17) 1651-1661
  CrossrefPubMedGoogle Scholar
• 78 Nalls MA, Duran R, Lopez G , et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013; 70 (6) 727-735
  CrossrefPubMedGoogle Scholar
• 79 Gegg ME, Burke D, Heales SJ , et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 2012; 72 (3) 455-463
  CrossrefPubMedGoogle Scholar
• 80 Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012; 11 (11) 986-998
  CrossrefPubMedGoogle Scholar
• 81 Manning-Boğ AB, Schüle B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009; 30 (6) 1127-1132
  CrossrefPubMedGoogle Scholar
• 82 Cullen V, Sardi SP, Ng J , et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 2011; 69 (6) 940-953
  CrossrefPubMedGoogle Scholar
• 83 Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 2011; 102 (4) 436-447
  CrossrefPubMedGoogle Scholar
• 84 Mazzulli JR, Xu YH, Sun Y , et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146 (1) 37-52
  CrossrefPubMedGoogle Scholar
• 85 Sato Y, Kaji M, Metoki N, Yoshida H, Satoh K. Coagulation-fibrinolysis abnormalities in patients receiving antiparkinsonian agents. J Neurol Sci 2003; 212 (1–2) 55-58
  CrossrefPubMedGoogle Scholar
• 86 Zibetti M, Rosso M, Cinquepalmi A , et al. Asymptomatic deep venous thrombosis after deep brain stimulation for Parkinson disease. Stereotact Funct Neurosurg 2010; 88 (2) 94-97
  CrossrefPubMedGoogle Scholar